Skip to content

This website is intended for UK healthcare professionals only

This is a promotional website developed by AstraZeneca

The prescribing information can be found at the bottom of the page

bars

Adaura Clinical Trial

Click on the infographic below for a full overview of the ADAURA trial and updated 5-year data


Background

The ADAURA trial was a double-blind, phase 3 trial which randomly assigned patients with completely resected EGFRm NSCLC to receive either Tagrisso (osimertinib) or placebo for 3 years.

Conclusion

Adjuvant TAGRISSO demonstrated a statistically significant and clinically meaningful improvement in OS vs. placebo in the recent 5-year readout of ADAURA, reiterating its long-term efficacy. In patients with stage II-IIIA disease (primary endpoint subset), the relative reduction in risk of death was 51%, HR: 0.49, 95.03% CI 0.33-0.73; P=0.0004, ARR: 10%.

New content coming soon

ADAURA Trial: 4 year DFS update

Dr Yvonne Summers, Consultant Medical Oncologist, Christie NHS Foundation Trust

Please click here for TAGRISSO GB prescribing information

Please click here for TAGRISSO NI prescribing information

ADAURA Trial: CNS recurrence data

Dr John Conibear, Consultant Clinical Oncologist, Barts Health NHS Trust

Please click here for TAGRISSO GB prescribing information

Please click here for TAGRISSO NI prescribing information

ADAURA Trial: Evolving UK clinical practice for EGFRm+ NSCLC

Dr Yvonne Summers, Consultant Medical Oncologist, Christie NHS Foundation Trust

Dr Shobhit Baijal, Consultant Medical Oncologist, Birmingham University Hospitals NHS Foundation Trust

Please click here for TAGRISSO GB prescribing information

Please click here for TAGRISSO NI prescribing information


References

  1. Tsuboi M, et al. Abstract LBA47. Presented at ESMO Congress, 9th–13th September 2022, Paris


BACK